GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evelo Biosciences Inc (OTCPK:EVLO) » Definitions » Forward PE Ratio

Evelo Biosciences (Evelo Biosciences) Forward PE Ratio : 0.00 (As of May. 05, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Evelo Biosciences Forward PE Ratio?

Evelo Biosciences's Forward PE Ratio for today is 0.00.

Evelo Biosciences's PE Ratio without NRI for today is 0.00.

Evelo Biosciences's PE Ratio for today is 0.00.


Evelo Biosciences Forward PE Ratio Historical Data

The historical data trend for Evelo Biosciences's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evelo Biosciences Forward PE Ratio Chart

Evelo Biosciences Annual Data
Trend
Forward PE Ratio

Evelo Biosciences Quarterly Data
Forward PE Ratio

Competitive Comparison of Evelo Biosciences's Forward PE Ratio

For the Biotechnology subindustry, Evelo Biosciences's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evelo Biosciences's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evelo Biosciences's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Evelo Biosciences's Forward PE Ratio falls into.



Evelo Biosciences Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Evelo Biosciences  (OTCPK:EVLO) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Evelo Biosciences Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Evelo Biosciences's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Evelo Biosciences (Evelo Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
620 Memorial Drive, 5th Floor, Cambridge, MA, USA, 02139
Evelo Biosciences Inc is a United States-based biotechnology company. It is engaged in discovering and developing a new class of orally delivered investigational medicines that are intended to act on cells in the small intestine to produce therapeutic effects throughout the body. Its lead product candidate under development is EDP1815, which is for the treatment of inflammatory diseases and the hyperinflammatory response associated with COVID-19. Other products in the pipeline include EDP1867 and EDP2939 for the treatment of inflammatory disease and EDP1908 for the treatment of cancer.
Executives
Simba Gill director, officer: President & CEO 515 GALVESTON DR, REDWOOD CITY CA 94063
Mark Bodmer officer: See Remarks C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Marella Thorell officer: Chief Financial Officer 1226 CHARTER LANE, AMBLER PA 19002
Duncan Mchale officer: Chief Medical Officer C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Alexander C Reynolds director C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Horizon Technology Finance Corp 10 percent owner 312 FARMINGTON AVENUE, FARMINGTON CT 06032
Jeffrey R. Moore director C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Flagship Ventures Fund Iv, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Robert L. Rosiello director 400 SOMERSET CORPORATE BOULEVARD, BRIDGEWATER NJ 08807
Stephen J Carriere officer: Principal Accounting Officer
David R Epstein director INTERNATIONAL FLAVORS & FRAGRANCES INC., 521 W. 57TH STREET, NEW YORK NY 10019
Lord Ara Darzi director C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Flagship Pioneering Fund Vii, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Flagship Pioneering Fund Vii General Partner Llc 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Tonya Williams director C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139